Solaxa announces plan for phase 3 clinical trial for SCA27b
In March, the pharmaceutical company Solaxa has announced plans to conduct a phase 3 clinical trial of their drug SLX-100 (repurposed 4-Aminopyridine) for Spinocerebellar ataxia 27b (SCA27b). The trial will […]
Solaxa announces plan for phase 3 clinical trial for SCA27b Read More »